Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$24.65 +0.9%	$21.94	$17.24 ▼ $27.94	$15.81B	0.95	1.17 million shs	1.39 million shs
RNA Avidity Biosciences	$46.35 +3.8%	$35.63	$21.51 ▼ $56.00	$5.96B	0.95	3.90 million shs	1.89 million shs
SMMT Summit Therapeutics	$26.20 +0.7%	$25.02	$11.76 ▼ $36.91	$19.46B	-1.06	2.81 million shs	2.22 million shs
TEVA Teva Pharmaceutical Industries	$18.47 -1.8%	$16.75	$12.47 ▼ $22.80	$21.17B	0.62	13.18 million shs	13.29 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+0.94%	+5.75%	+7.78%	+18.45%	-10.33%
RNA Avidity Biosciences	+3.78%	-0.26%	+36.65%	+51.57%	+2.95%
SMMT Summit Therapeutics	+0.73%	-1.84%	-6.46%	+1.35%	+96.40%
TEVA Teva Pharmaceutical Industries	-1.73%	+3.39%	+11.41%	+8.98%	+1.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.8549 of 5 stars	3.3	4.0	3.2	0.0	3.1
RNA Avidity Biosciences	3.1767 of 5 stars	4.5	2.0	3.9	0.8	0.0
SMMT Summit Therapeutics	2.3705 of 5 stars	4.3	1.0	1.9	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.9425 of 5 stars	3.6	4.0	3.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.60	52.54% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	44.55% Upside
SMMT Summit Therapeutics	2.63	Moderate Buy	$32.85	25.37% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	33.84% Upside

Current Analyst Ratings Breakdown

Latest RNA, TEVA, SMMT, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$21.00
8/19/2025	GMAB Genmab A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
8/18/2025	SMMT Summit Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$21.00
8/15/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
8/15/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
8/14/2025	SMMT Summit Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $34.00
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.26B	4.85	$1.53 per share	16.10	$8.26 per share	2.98
RNA Avidity Biosciences	$10.90M	547.06	N/A	N/A	$9.27 per share	5.00
SMMT Summit Therapeutics	$700K	27,803.81	N/A	N/A	$0.35 per share	74.86
TEVA Teva Pharmaceutical Industries	$16.54B	1.28	$3.30 per share	5.59	$5.96 per share	3.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.99	12.39	13.85	7.09	37.53%	21.03%	16.98%	11/5/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$1.01	N/A	N/A	N/A	N/A	-208.64%	-181.28%	10/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.02	1.11	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest RNA, TEVA, SMMT, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	-$0.76	-$0.66	-$0.76	N/A	N/A
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	6.22	6.20
RNA Avidity Biosciences	N/A	9.26	9.26
SMMT Summit Therapeutics	N/A	5.13	5.13
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
RNA Avidity Biosciences	N/A
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
RNA Avidity Biosciences	3.83%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable
SMMT Summit Therapeutics	110	742.85 million	112.17 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

RNA, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

Atika Capital Management LLC Invests $6.72 Million in Teva Pharmaceutical Industries Ltd. $TEVA

August 23 at 7:48 AM | marketbeat.com

Teva Pharmaceutical: Tariff Relief Clears The Way For Reinvention

August 22 at 2:08 PM | seekingalpha.com

Banco BTG Pactual S.A. Has $571,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 22 at 7:10 AM | marketbeat.com

Northwest & Ethical Investments L.P. Has $548,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 22 at 4:43 AM | marketbeat.com

Aberdeen Group plc Acquires 286,206 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 21 at 4:18 AM | marketbeat.com

State of New Jersey Common Pension Fund D Buys 41,300 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 20 at 6:04 AM | marketbeat.com

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

August 20 at 3:51 AM | fool.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $4.49 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 19, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by National Bank of Canada FI

August 19, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Lifted by Menora Mivtachim Holdings LTD.